Curis, Inc. (CRIS) vs TransCode Therapeutics, Inc. (RNAZ)
A side-by-side comparison of Curis, Inc. and TransCode Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRIS
Curis, Inc.
$0.74HealthcareDelayed quote: Oct 6, 2026, 3:51 PM EDT
RNAZ
TransCode Therapeutics, Inc.
$1.76HealthcareDelayed quote: Oct 6, 2026, 3:49 PM EDT
Total return — CRIS vs RNAZ
growth of $100 · dividends reinvested · last 5yCRIS -100.0% (-80.8%/yr)RNAZ -100.0% (-94.2%/yr)CRIS compounded faster over this window
Log scale — wide-divergence pair
CRIS RNAZ
CRIS vs RNAZ: by the numbers
- •RNAZ is the larger company ($2M vs $1M market cap).
- •Both run net losses; RNAZ's is the smaller (0.00% vs -490.33% net margin).
Metrics side by side
Valuation
| Metric | CRIS | RNAZ |
|---|---|---|
| P/S ratio | 0.33 | N/A |
| P/B ratio | 0.31 | N/A |
Profitability
| Metric | CRIS | RNAZ |
|---|---|---|
| Gross margin | 99.28% | 0.00% |
| Operating margin | -348.43% | 0.00% |
| Net margin | -490.33% | 0.00% |
| ROE | -450.54% | -30.92% |
| ROIC | -567.17% | -23.73% |
Growth (annualized)
| Metric | CRIS | RNAZ |
|---|---|---|
| Revenue CAGR (5Y) | -15.88% | N/A |
| Total return CAGR (5Y) | -81.06% | -93.39% |
Frequently asked
- How have CRIS and RNAZ total returns compared?
- Over the past 5 years, CRIS delivered -81.06% and RNAZ delivered -93.39% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.